| Aug 23, 2022 |
2022 FC 1218 |
Janssen v. Pharmascience
We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitat...
|
Patents
|
|
| Jan 31, 2022 |
2022 FC 107 |
Janssen v Apotex
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s ...
|
Patents
|
|
| Jan 19, 2022 |
2022 FC 62 |
Janssen v Pharmascience
We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen&r...
|
Patents
|
|
| Jan 14, 2021 |
2021 FC 7 |
Janssen v Apotex, Pharmascience and Dr. Reddy’s Laboratories
We represented Janssen and BTG in these patent infringement actions relating to Janssen’s prostate cancer product ZYTIGA®(abiraterone ace...
|
Patents
|
|
| May 5, 2020 |
2020 FC 593 |
Janssen Inc. et al v Teva Canada Limited
We successfully represented Janssen in this patent infringement action under the new PMNOC Regulations concerning Janssen’s Invega Sustenna (...
|
Patents
|
|
| Jul 13, 2018 |
2018 FC 736 |
Eli Lilly Canada Inc. et al v. Apotex Inc.
We represented Eli Lilly, Daiichi and Ube in this application relating to a patent covering Eli Lilly’s EFFIENT product.
|
Patents
|
|
| Apr 10, 2018 |
Federal Court File Nos. T-598-17 through T-605-17 |
AbbVie Corporation et al v Samsung Bioepis Co. Ltd.
We represented AbbVie in a series of eight applications under the PMNOC Regulations relating to AbbVie’s blockbuster drug HUMIRA. The c...
|
Patents
|
|
| Apr 9, 2018 |
Federal Court File No. T-1355-17 |
Samsung Bioepis Co., Ltd. v AbbVie Biotechnology Ltd. et al.
We represented AbbVie in a patent impeachment action brought by Samsung Bioepis in relation to Samsung Bioepis’ biosimilar to AbbVIe’s ...
|
Patents
|
|
| Dec 9, 2016 |
2016 FC 1361 |
Janssen Inc. et al. v. Actavis Pharma Company et al.
We successfully represented Janssen in a patent case relating to the ADHD medication CONCERTA. The generic company Actavis Pharma had challen...
|
Patents
|
|
| May 31, 2016 |
2016 FC 593 |
Janssen Inc. v. Teva Canada Limited
We successfully represented Janssen in this action for damages resulting from infringement of the patent covering Janssen’s LEVAQUIN product....
|
Patents
|
|
| Sep 16, 2015 |
2015 FCA 192 |
Actavis Pharma Company v. Alcon Canada Inc.
We successfully represented Alcon and Bayer in this appeal brought by Actavis. The Federal Court had upheld the validity of Bayer’s patent re...
|
Patents
|
|
| Aug 31, 2015 |
Court File No. T-2247-14 |
Sanofi-Aventis Canada Inc. v. Eli Lilly Canada Inc.
We successfully represented Eli Lilly in a patent proceeding relating to Eli Lilly’s diabetes medicine BASAGLAR. After filing a motion to dis...
|
Patents
|
|
| Oct 28, 2014 |
2014 FCA 242 |
Janssen Inc. v. Abbvie Corporation
We successfully represented Janssen on this appeal from a refusal to grant an amendment to Janssen’s pleading. The Court of Appeal agre...
|
Patents
|
|
| May 14, 2014 |
2014 FC 462 |
Alcon Canada Inc. v. Cobalt Pharmaceuticals Company
We successfully defended the validity of Bayer’s patent covering the antibiotic moxifloxacin (AVELOX® and VIGAMOX ®) and obtaine...
|
Patents
|
|
| Apr 11, 2012 |
2012 FC 410 |
Alcon Canada Inc. v. Apotex Inc.
We represented Alcon in a proceeding under the PMNOC Regulations relating to PATANOL.
|
Patents
|
|
| May 12, 2010 |
2010 FC 42 |
Janssen-Ortho Inc. v. Canada (Health)
We represented Janssen-Ortho and Alza Corporation in a proceeding under the PMNOC Regulations relating to CONCERTA®.
|
Patents
|
|